Literature DB >> 4018844

Effect of FUT-175, a new synthetic protease inhibitor, on the development of lupus nephritis in (NZB x NZW) F1 mice.

S Ikehara, K Shimamura, T Aoyama, S Fujii, Y Hamashima.   

Abstract

FUT-175 (6-amidino-2-naphthyl p-guanidinobenzoate dimethanesulphonate), a new synthetic protease inhibitor, was administrated to (NZB x NZB) F1 mice in order to examine its influence on the development of autoimmune diseases. A dose (400 mg/kg of body weight) of FUT-175 has both prophylactic and curative effects on the development of lupus nephritis: mice showed a significantly low percentage of proteinuria, a marked decrease in BUN levels, and the lowest degree of glomerular damages. Dexamethasone had almost the same effect as FUT-175 (400 mg/kg), but it was slightly less effective than FUT-175. These results suggest that the administration of FUT-175 may become a viable strategy for the treatment of human autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4018844      PMCID: PMC1453784     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  13 in total

1.  The effect of complement depletion by cobra venom factor on delayed hypersensitivity reactions.

Authors:  H J Schwartz; G B Naff
Journal:  Proc Soc Exp Biol Med       Date:  1971-12

2.  Depletion of plasma complement in vivo by a protein of cobra venom: its effect on various immunologic reactions.

Authors:  C G Cochrane; H J Müller-Eberhard; B S Aikin
Journal:  J Immunol       Date:  1970-07       Impact factor: 5.422

3.  Suppression of contact hypersensitivity and acute inflammation by anti-complement serum.

Authors:  D A Willoughby; L Polák; J L Turk
Journal:  Nature       Date:  1968-07-13       Impact factor: 49.962

Review 4.  Etiopathogenesis of murine SLE.

Authors:  A N Theofilopoulos; F J Dixon
Journal:  Immunol Rev       Date:  1981       Impact factor: 12.988

5.  Complement inhibition by amidines and guanidines--in vivo and in vitro results.

Authors:  I G Otterness; A J Torchia; H D Doshan
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

6.  Role of complement in the expression of delayed-type hypersensitivity in rats: studies with cobra venom factor.

Authors:  T W Jungi; D D McGregor
Journal:  Infect Immun       Date:  1979-03       Impact factor: 3.441

7.  New synthetic inhibitor to the alternative complement pathway.

Authors:  N Ikari; Y Sakai; Y Hitomi; S Fujii
Journal:  Immunology       Date:  1983-08       Impact factor: 7.397

8.  Marked reduction of DNA antibody production and glomerulopathy in thymulin (FTS-Zn) or cyclosporin A treated (NZB X NZW) F1 mice.

Authors:  D Israel-Biet; L H Noel; M A Bach; M Dardenne; J F Bach
Journal:  Clin Exp Immunol       Date:  1983-11       Impact factor: 4.330

9.  New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin.

Authors:  S Fujii; Y Hitomi
Journal:  Biochim Biophys Acta       Date:  1981-10-13

10.  Inhibition of various immunological reactions in vivo by a new synthetic complement inhibitor.

Authors:  Y Hitomi; S Fujii
Journal:  Int Arch Allergy Appl Immunol       Date:  1982
View more
  5 in total

1.  Autoimmune kidney disease in MRL/Mp-lpr/lpr mice inhibited by OK-432, a streptococcal preparation.

Authors:  M Mihara; Y Ohsugi
Journal:  Clin Exp Immunol       Date:  1989-10       Impact factor: 4.330

Review 2.  The treatment of immune glomerular disease.

Authors:  D G Williams
Journal:  Springer Semin Immunopathol       Date:  1987

3.  Protective effects of nafamostat mesilate on liver injury induced by lipopolysaccharide in rats: possible involvement of CD14 and TLR-4 downregulation on Kupffer cells.

Authors:  Hideaki Miyaso; Yoshinori Morimoto; Michitaka Ozaki; Sanae Haga; Susumu Shinoura; Yasuhiro Choda; Hiroshi Murata; Goutaro Katsuno; Kamul Huda; Hideo Takahashi; Noriaki Tanaka; Hiromi Iwagaki
Journal:  Dig Dis Sci       Date:  2006-10-28       Impact factor: 3.199

4.  Amelioration of immune complex-mediated glomerulonephritis by synthetic protease inhibitors.

Authors:  J C Jennette; R R Tidwell; J D Geratz; D H Bing; R J Falk
Journal:  Am J Pathol       Date:  1987-06       Impact factor: 4.307

5.  Effect of oral camostat mesilate on hematuria and/or proteinuria in children.

Authors:  Tadashi Asami; Shuichi Tomisawa; Makoto Uchiyama
Journal:  Pediatr Nephrol       Date:  2004-01-23       Impact factor: 3.714

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.